We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App




LGC Clinical Diagnostics Acquires Urinalysis Quality Controls Provider Kova International

By LabMedica International staff writers
Posted on 25 Jul 2023
Print article
Image: KOVA-Trol and KOVA Liqua-Tro urinalysis controls are intended for use in the clinical laboratory (Photo courtesy of Kova International)
Image: KOVA-Trol and KOVA Liqua-Tro urinalysis controls are intended for use in the clinical laboratory (Photo courtesy of Kova International)

LGC Clinical Diagnostics (Middlesex, UK), a business unit of LGC and a leading provider of biological materials and viral antigens, has acquired Kova International, Inc. (Garden Grove, CA, USA), a developer and manufacturer of in vitro urinalysis and toxicology quality control products for clinical laboratories. Kova has two manufacturing facilities, one focusing on urinalysis quality controls and the other on toxicology quality controls. Both the manufacturing facilities are certified to ISO 13485:2016 quality management system standards and guidelines, as well as cGMP qualified to manufacture quality control products, and are registered FDA manufacturing sites for the clinical diagnostic laboratory industry.

Kova’s quality control products are employed in hospitals, employee wellness programs, forensic testing and medical device manufacturers production and Quality Assurance (QA) programs. The acquisition expands LGC Clinical Diagnostics’ clinical quality control portfolio, complementing its wide range of offerings across biochemistry, serology, molecular, and clinical genomics quality controls and reference materials. LGC Clinical Diagnostics has over 35 years of industry experience and caters to more than 20,000 customers in over 100 counties. The company is keen on combining Kova’s expertise with its own in order to offer its customers unmatched solutions with expanded capabilities.

“We are excited to bring Kova’s established clinical urinalysis and toxicology quality controls into LGC Clinical Diagnostics,” said Bharathi Anekella, Executive Vice President & General Manager of LGC Clinical Diagnostics. “Kova and LGC Clinical Diagnostics are an excellent fit. Our focus on delivering confidence to clinical laboratories in test precision, accuracy, and conformance to international standards, perfectly aligns us with a common objective of Science for a Safer World.”

Related Links:
LGC
Kova International, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.